GigaMune wins its seventh SBIR grant

GigaMune won its seventh SBIR grant, entitled “Delivery of Full Length Dystrophin to Muscle Cells for DMD Gene Therapy” from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). The project seeks to expand the capabilities of GigaMune’s technology into delivery of curative transgenes to muscle cells. GigaMune’s Founder and CEO Dr. David Johnson is principal investigator (PI) on the project. This is Dr. Johnson’s nineteenth SBIR grant as PI.